

NOVO NORDISK A S
Form 6-K
April 30, 2013

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

April 30, 2013

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 30 April 2013 – On 31 January 2013 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk has repurchased B shares for an amount of DKK 3.0 billion in the period from 31 January 2013 to 29 April 2013. The programme is now concluded.

Since the announcement as of 22 April 2013, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	2,811,810		2,756,147,078
22 April 2013	55,000	951.59	52,337,467
23 April 2013	40,000	951.12	38,044,708
24 April 2013	45,000	973.96	43,827,984
25 April 2013	50,000	981.60	49,079,930
29 April 2013	60,000	993.04	59,582,268
Accumulated under the programme	3,061,810		2,999,019,435

With the transactions stated above, Novo Nordisk owns a total of 10,645,508 treasury shares, corresponding to 1.9% of the share capital. The total amount of shares in the company is 550,000,000 including treasury shares.

Novo Nordisk A/S Novo Allé
Investor Relations 2880 Bagsværd

Telephone:
+45 4444 8888

CVR no:
24 25 67 90

Denmark

Internet:
www.novonordisk.com

Company announcement No 30 / 2013

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12 month period beginning 31 January 2013. As of 29 April 2013, Novo Nordisk has repurchased a total of 3,061,810 B shares equal to a transaction value of DKK 2,999,019,435.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 514 8316	kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen	+45 4442 4303	krop@novonordisk.com
Frank Daniel Mersebach	+45 4442 0604	fdni@novonordisk.com
Lars Borup Jacobsen	+45 3075 3479	lbpj@novonordisk.com
Jannick Lindegaard (US)	+1 609 786 4575	jlis@novonordisk.com

Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark

Telephone: +45 4444 8888
CVR no: 24 25 67 90
Internet: www.novonordisk.com

Company announcement No 30 / 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: April 30, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer